| __timestamp | AstraZeneca PLC | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 5579000000 | 100244000 |
| Thursday, January 1, 2015 | 5997000000 | 29674000 |
| Friday, January 1, 2016 | 5890000000 | 14917000 |
| Sunday, January 1, 2017 | 5757000000 | 14118000 |
| Monday, January 1, 2018 | 5932000000 | 8737000 |
| Tuesday, January 1, 2019 | 5958000000 | 6900000 |
| Wednesday, January 1, 2020 | 5991000000 | 6248000 |
| Friday, January 1, 2021 | 9736000000 | 12312000 |
| Saturday, January 1, 2022 | 9762000000 | 19721000 |
| Sunday, January 1, 2023 | 10935000000 | 31283000 |
Data in motion
In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, AstraZeneca PLC has consistently outpaced MannKind Corporation in R&D investments. From 2014 to 2023, AstraZeneca's R&D expenses surged by nearly 96%, peaking at approximately $10.9 billion in 2023. In contrast, MannKind's R&D budget saw a decline, with a notable drop of around 69% from its 2014 high of $100 million to just over $31 million in 2023.
This stark difference highlights AstraZeneca's robust strategy to maintain its competitive edge through innovation, while MannKind's reduced spending may reflect strategic shifts or financial constraints. As the pharmaceutical landscape evolves, these R&D trends could significantly impact each company's future growth and market positioning.
AstraZeneca PLC vs Verona Pharma plc: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for AstraZeneca PLC and Iovance Biotherapeutics, Inc.
Research and Development Investment: AstraZeneca PLC vs Celldex Therapeutics, Inc.
R&D Insights: How Novartis AG and MannKind Corporation Allocate Funds
Research and Development: Comparing Key Metrics for Pfizer Inc. and MannKind Corporation
Teva Pharmaceutical Industries Limited vs MannKind Corporation: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and MannKind Corporation
R&D Insights: How Verona Pharma plc and MannKind Corporation Allocate Funds
R&D Spending Showdown: Perrigo Company plc vs MannKind Corporation
Research and Development Investment: Vericel Corporation vs MannKind Corporation
R&D Insights: How MannKind Corporation and Taro Pharmaceutical Industries Ltd. Allocate Funds